Longevity

All-day "executive physical" experiences with stacks of advanced tests—the yield-versus-harm math of what you actually detect earlier.

IV NAD+ as longevity intervention—the biochemistry is real, but human evidence for anti-aging benefits remains limited.

HBOT for longevity—Israeli telomere studies, the FDA's warnings, and why Silicon Valley is buying chambers.

From young blood transfusions to plasma dilution—the science behind removing "aging factors" from circulation.

The global market for unregulated stem cell therapies—what the science supports versus what clinics promise.

Flying to access treatments unavailable at home—the geography of regulatory arbitrage in longevity medicine.

Vitrification and long-term preservation—the science of cryopreservation versus the faith in future technology.